Volume 4, 2013 | In This Issue
2013: Celebrating a Year of Accomplishments >
Collaboration to Accelerate Pace of Lupus Research >
TREX1 Gene Mutation: An Avenue to Target Lupus >
Getting One Walk Up and Running while Another Approaches $1 Million Threshold >
A Grateful Message to the ALR Family of Supporters >
Lupus News Corner >
Collaboration to Accelerate Pace of Lupus Research
The Alliance for Lupus Research (ALR) and the Lupus Research Institute (LRI) have joined forces with a single aim in mind: Speed the identification and availability of new treatments for lupus.
The focus of this collaboration is to identify therapies that have already been approved for other conditions — such as multiple sclerosis, rheumatoid arthritis, transplant rejection, and cancer — which might be effective in treating lupus.
An initial look at all of the available drugs and treatments looks promising. So far, approximately 70 possible therapies for lupus have been revealed.
The two organizations hope to produce a comprehensive, evidence-based analysis that will fully document and prioritize each potential lupus therapy. Decisions will be based on safety profile, availability, feasibility to carry out a trial, and likelihood to succeed in alleviating the devastating, painful symptoms associated with lupus.
Peter E. Lipsky, MD, who also serves on the ALR’s Scientific Advisory Board, is heading up this project as Scientific Coordinator. “This process should accelerate the identification of new therapeutic candidates with real potential to improve lives of patients with lupus and contribute to de-risking the process of developing new treatments for the disease,” said Dr. Lipsky.